NCT06164951: An ongoing trial by QED Therapeutics, a BridgeBio company
This trial is ongoing. It must report results 7 months, 4 weeks from now.
Full data
| Full entry on ClinicalTrials.gov | NCT06164951 |
|---|---|
| Title | A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Infigratinib in Children 3 to <18 Years of Age With Achondroplasia: PROPEL 3 |
| Results Status | Ongoing |
| ACT or pACT? | This is what FDAAA officially calls an "Applicable Clinical Trial" |
| Start date | Nov. 10, 2023 |
| Completion date | Dec. 18, 2025 |
| Required reporting date | Dec. 18, 2026, midnight |
| Actual reporting date | None |
| Date last checked at ClinicalTrials.gov | April 23, 2026 |
| Days late | None |